CN112004923A - 细胞组合物及治疗方法 - Google Patents

细胞组合物及治疗方法 Download PDF

Info

Publication number
CN112004923A
CN112004923A CN201880083837.3A CN201880083837A CN112004923A CN 112004923 A CN112004923 A CN 112004923A CN 201880083837 A CN201880083837 A CN 201880083837A CN 112004923 A CN112004923 A CN 112004923A
Authority
CN
China
Prior art keywords
mir
hsa
cells
mesenchymal lineage
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880083837.3A
Other languages
English (en)
Chinese (zh)
Inventor
P·布林克
I·科恩
R·林
S·多罗尼
I·波塔波瓦
V·瓦里尤纳斯
D·迪瓦恩
A·桑德拉萨格拉
N·罗伊左斯
S·伊茨库
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Priority to CN202411189619.1A priority Critical patent/CN119033819A/zh
Publication of CN112004923A publication Critical patent/CN112004923A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01214—Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880083837.3A 2017-11-22 2018-11-21 细胞组合物及治疗方法 Pending CN112004923A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411189619.1A CN119033819A (zh) 2017-11-22 2018-11-21 细胞组合物及治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589764P 2017-11-22 2017-11-22
US62/589,764 2017-11-22
PCT/IB2018/001439 WO2019102268A1 (en) 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411189619.1A Division CN119033819A (zh) 2017-11-22 2018-11-21 细胞组合物及治疗方法

Publications (1)

Publication Number Publication Date
CN112004923A true CN112004923A (zh) 2020-11-27

Family

ID=65003422

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880083837.3A Pending CN112004923A (zh) 2017-11-22 2018-11-21 细胞组合物及治疗方法
CN202411189619.1A Pending CN119033819A (zh) 2017-11-22 2018-11-21 细胞组合物及治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411189619.1A Pending CN119033819A (zh) 2017-11-22 2018-11-21 细胞组合物及治疗方法

Country Status (10)

Country Link
US (2) US12473547B2 (https=)
EP (1) EP3714038A1 (https=)
JP (2) JP7463275B2 (https=)
KR (2) KR20250051794A (https=)
CN (2) CN112004923A (https=)
AU (1) AU2018372631B2 (https=)
BR (1) BR112020010079A2 (https=)
CA (1) CA3084575A1 (https=)
SG (1) SG11202004680UA (https=)
WO (1) WO2019102268A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654705A (zh) * 2018-09-11 2021-04-13 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用在治疗代谢疾病中的微小rna抑制剂
CN113025714A (zh) * 2021-03-23 2021-06-25 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
CN113621708A (zh) * 2020-03-30 2021-11-09 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN118831092A (zh) * 2024-09-19 2024-10-25 天津市第五中心医院 miR-200b-3p在制备治疗子宫内膜癌的药物中的应用
CN119144728A (zh) * 2024-11-19 2024-12-17 四川大学华西医院 原发性肝癌的MicroRNA标志物的引物、试剂盒和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CN112067805B (zh) * 2020-08-25 2023-08-22 南通大学 一种β-1,4-半乳糖基转移酶-IsiRNA在克服肝癌化疗耐药药物中的应用
EP4384621A4 (en) * 2021-08-09 2025-04-09 The Trustees of The University of Pennsylvania OPTIMIZATION OF T LYMPHOCYTE DIFFERENTIATION STATE WITH MICRORNAS
CN114085817B (zh) * 2021-11-26 2025-04-15 三代康年(上海)医疗科技有限公司 一种包载microRNA的外泌体的制备方法及其产品和应用
WO2023109911A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Microglia having car and use thereof
US20240318185A1 (en) * 2023-03-20 2024-09-26 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived microribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141177A1 (en) * 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Methods and compositions for the treatment of sarcoma
US20090163434A1 (en) * 2006-12-08 2009-06-25 Bader Andreas G miR-20 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20120114618A1 (en) * 2009-03-26 2012-05-10 The Regents Of The University Of California Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
US20150024966A1 (en) * 2012-02-22 2015-01-22 Brainstem Biotec Ltd. Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
US20150329875A1 (en) * 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2017165641A1 (en) * 2016-03-23 2017-09-28 The Trustees Of Columbia University In The City Of New York CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
CA2192103C (en) 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643736A (en) 1995-02-06 1997-07-01 Osiris Therapeutics, Inc. Monoclonal antibodies for human osteogenic cell surface antigens
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
ATE329603T1 (de) 1995-03-28 2006-07-15 Univ Jefferson Implantat mit immunisolierten stromazellen und deren verwendung
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
CA2237890C (en) 1995-11-16 2011-03-29 Case Western Reserve University In vitro chondrogenic induction of human mesenchymal stem cells
US6482231B1 (en) 1995-11-20 2002-11-19 Giovanni Abatangelo Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
ATE439849T1 (de) 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
JP2000508922A (ja) 1996-04-26 2000-07-18 ケース ウエスターン リザーブ ユニバーシティ 間葉幹細胞を用いる皮膚再生
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2271758A1 (en) 1996-11-15 1998-05-22 Osiris Therapeutics, Inc. Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes
DE69837491T2 (de) 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. Menschliche mesenchymale stammzellen aus peripherem blut
US6387369B1 (en) 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6149906A (en) 1997-09-20 2000-11-21 Osiris Therapeutics, Inc. Antigen presenting cells of the adipocyte lineage
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6328960B1 (en) 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
AU2904199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
PT1066060E (pt) 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
EP1078042A1 (en) 1998-05-22 2001-02-28 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
AU4221399A (en) 1998-05-29 1999-12-13 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
EP1108011A2 (en) 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
DE69937888T2 (de) 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Verfahren zur Herstellung mesenchymaler Stammzellen
WO2000029001A1 (en) 1998-11-13 2000-05-25 Osiris Therapeutics, Inc. Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
US6761887B1 (en) 1998-11-16 2004-07-13 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
AU2998300A (en) 1999-02-17 2000-09-04 United States Surgical Corporation Genetically altered mesenchymal stem cells and methods of use thereof
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2001021767A2 (en) 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
AU5723601A (en) 2000-04-25 2001-11-07 Osiris Therapeutics Inc Joint repair using mesenchymal stem cells
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
WO2002008389A2 (en) 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7144729B2 (en) 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1279738A1 (en) 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
WO2003018077A1 (en) 2001-08-22 2003-03-06 National Institute Of Advanced Industrial Science And Technology Method of bone regeneration
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
US20050048036A1 (en) 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050008626A1 (en) 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
KR100930139B1 (ko) 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
BR0306902A (pt) 2002-01-14 2006-04-11 Ford Henry Health System materiais de células estromais de medula óssea para uso na formação de vasos sanguìneos e produção de fatores angiogênicos e tróficos
WO2003080083A1 (es) 2002-03-26 2003-10-02 Oncolytics Biotech Inc. Uso de adenovirus mutados en los genes va para el tratamiento del cancer
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
CN1187058C (zh) 2002-04-16 2005-02-02 中国医学科学院血液学研究所泰达生命科学技术研究中心 用于修复中枢神经损伤的干细胞制剂及其制造方法
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
DK1513877T3 (da) 2002-06-14 2008-06-02 Cartela Ab Markör for stamceller og dens anvendelse
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
JP2005532810A (ja) 2002-07-16 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 組織修復および組織形成のために間葉性幹細胞を移植する方法
AU2003259152A1 (en) 2002-07-23 2004-02-09 Boston Scientific Limited Cell therapy for regeneration
US7732203B2 (en) 2002-08-17 2010-06-08 Ajoll University Industry Cooperation Foundation Method for transdifferentiating mesenchymal stem cells into neuronal cells
US20060110359A1 (en) 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
CN1536075A (zh) 2003-04-09 2004-10-13 中国人民解放军军事医学科学院野战输 一种诱导骨髓间充质干细胞向胰岛样细胞分化的方法
CH700956B1 (de) 2003-05-08 2010-11-15 Cellartis Ab Gefrierkonservierung menschlicher, von Blastocysten abgeleiteten Stammzellen nach dem Verfahren der Vitrifizierung im geschlossenen Röhrchen.
WO2005059111A2 (en) 2003-12-17 2005-06-30 The Trustees Of Columbia University In The City Of New York DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
TR201901268T4 (tr) 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US20060063141A1 (en) 2004-09-17 2006-03-23 Mcgann Locksley E Method of cryopreserving cells
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
JP5162756B2 (ja) 2005-04-14 2013-03-13 財団法人ヒューマンサイエンス振興財団 医薬組成物及びその製造方法
WO2006113881A2 (en) 2005-04-19 2006-10-26 The Johns Hopkins University Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood
JP2009500297A (ja) 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
EP1937801A1 (en) 2005-09-02 2008-07-02 Agency for Science, Technology and Research Method of deriving mesenchymal stem cells
US7888119B2 (en) 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20090274665A1 (en) 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
AU2007243221A1 (en) 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
US20100047216A1 (en) 2006-07-21 2010-02-25 Glenn Gaudette Compositions of late passage mesenchymal stem cells (mscs)
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
ES2663875T3 (es) 2006-11-03 2018-04-17 Multiple Sclerosis Research Center Of New York Células madre mesenquimáticas derivadas de la médula ósea como fuente de progenitores neurales
CA2913024A1 (en) 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
TW200902718A (en) 2007-03-01 2009-01-16 Cryo Cell Int Procurement, isolation, and cryopreservation of endometrial/menstrual cells
JP5746823B2 (ja) 2007-03-14 2015-07-08 インスティトゥト カタラ ドンコロジア Ｅ３−１９ｋタンパク質の小胞体保持ドメインに突然変異を有するアデノウイルス及び癌治療におけるその用途
US9095562B2 (en) 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
US20100040583A1 (en) 2008-03-27 2010-02-18 Vincent Falanga Compositions and methods using stem cells in cutaneous wound healing
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
JP2011529706A (ja) 2008-08-04 2011-12-15 アローキュア インコーポレイテッド 間充織間質細胞集団、ならびにそれを単離および使用する方法
EP3124601A1 (en) 2008-08-14 2017-02-01 Mesoblast International Sàrl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2485741A4 (en) 2009-10-06 2013-07-24 Cohen Mcniece Foundation PREPARATION AND USE OF STROMAL CELLS FOR THE TREATMENT OF CARDIAC DISORDERS
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
CN103502437B (zh) 2010-07-20 2016-08-03 南加州大学 高端粒酶活性的骨髓间充质干细胞、其制造方法和基于其的药物和治疗方法
PT2611906T (pt) 2010-08-31 2024-04-16 Gallant Pet Inc Terapias sistémicas com células estaminais alogénicas para tratamento de doenças em gatos e cães
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
AU2011325439B2 (en) 2010-11-02 2015-07-23 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Methods and vectors for cell immortalisation
US8748470B2 (en) * 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
FI125055B (fi) 2011-04-07 2015-05-15 Oy Langh Ship Ab Kontti
KR101920277B1 (ko) 2011-06-03 2018-11-20 메소블라스트, 아이엔씨. 뇌졸중 증상을 치료하는 방법
CN104508124B (zh) 2011-07-06 2017-11-17 细胞治疗有限公司 中胚层谱系祖细胞
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
HUE043785T2 (hu) 2013-03-13 2019-09-30 Wisconsin Alumni Res Found Módszerek és anyagok humán pluripotens õssejtek hematoendothelialis differenciálására meghatározott körülmények között
EP3010519B1 (en) 2013-06-18 2021-04-07 Dnatrix Inc. Oncolytic adenovirus for use in a treatment of brain cancer
WO2015016761A2 (en) 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
ES2984009T3 (es) 2013-11-04 2024-10-28 Isopogen Pty Ltd Método de cultivo celular
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
SG11201607925SA (en) 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
WO2016086020A1 (en) * 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
JP7315301B2 (ja) 2014-12-23 2023-07-26 メゾブラスト・インターナショナル・エスアーエールエル 進行性心不全の予防
EP4008775A1 (en) 2015-03-04 2022-06-08 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
AU2016258980B2 (en) 2015-05-05 2022-02-17 Mesoblast International Sàrl Potency assay
WO2017132358A1 (en) 2016-01-26 2017-08-03 Kansas State University Research Foundation Methods for isolation and expansion of umbilical cord mesenchymal stem cells
EP3419635B1 (en) 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US20180021380A1 (en) 2016-07-21 2018-01-25 Sungkwang Medical Foundation Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same
US20200085890A1 (en) 2016-07-29 2020-03-19 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
CA3037333A1 (en) 2016-09-19 2018-03-22 University Of South Florida Method of targeting oncolytic viruses to tumors
US20200108099A1 (en) 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
WO2018182612A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
CL2017002357A1 (es) 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
CA3082368A1 (en) 2017-11-09 2019-05-16 Sapporo Medical University Medicine for tissue regeneration, and preparation method therefor
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CN108715833B (zh) 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
KR20200015174A (ko) 2018-08-03 2020-02-12 이동희 3차원 세포 배양 지지체 및 이를 포함하는 줄기세포 배양 조성물
JP2022515916A (ja) 2019-01-02 2022-02-22 メゾブラスト・インターナショナル・エスアーエールエル 腰痛を治療するための方法
AU2020204809A1 (en) 2019-01-03 2021-07-29 Mesoblast International Sàrl Method for improving visual acuity
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
CN113853206A (zh) 2019-05-23 2021-12-28 迈索布拉斯特国际有限公司 脑梗塞的功能恢复
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
AU2020325825B2 (en) 2019-08-05 2026-02-05 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
KR20220143092A (ko) 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
CN111297899A (zh) 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用
CA3170255A1 (en) 2020-03-05 2021-09-10 Silviu Itescu Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
WO2021180850A1 (en) 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease i
WO2021180851A1 (en) 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease ii
BR112022020042A2 (pt) 2020-04-03 2022-11-22 Mesoblast Int Sarl Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
JP2023530098A (ja) 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CA3188492A1 (en) 2020-08-10 2022-02-17 Silviu Itescu Cellular compositions and methods of treatment
AU2021403025A1 (en) 2020-12-15 2023-07-20 Mesoblast International Sarl Method of treating progressive heart failure in subjects with class ii heart failure
CN112522191B (zh) 2020-12-18 2023-05-12 云南中科灵长类生物医学重点实验室 一种间充质干细胞的培养方法
JP2024504148A (ja) 2021-01-22 2024-01-30 メゾブラスト・インターナショナル・エスアーエールエル オピオイド節減組成物及びその使用方法
BR112023021840A2 (pt) 2021-04-23 2024-02-06 Mesoblast Int Sarl Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
KR20250133306A (ko) 2022-12-09 2025-09-05 메조블라스트 인터내셔널 에스에이알엘 사전 허가된 조성물 및 세포 배양 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163434A1 (en) * 2006-12-08 2009-06-25 Bader Andreas G miR-20 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2008141177A1 (en) * 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Methods and compositions for the treatment of sarcoma
US20120114618A1 (en) * 2009-03-26 2012-05-10 The Regents Of The University Of California Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
US20150024966A1 (en) * 2012-02-22 2015-01-22 Brainstem Biotec Ltd. Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
US20150329875A1 (en) * 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2017165641A1 (en) * 2016-03-23 2017-09-28 The Trustees Of Columbia University In The City Of New York CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LINE GROTH-PEDERSEN等: "Identification of Cytoskeleton-Associated Proteins Essential for Lysosomal Stability and Survival of Human Cancer Cells", PLOS ONE, vol. 7, no. 10, 31 October 2012 (2012-10-31) *
MENG JIANG等: "KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells", ONCOTARGET, vol. 8, no. 54, 30 September 2017 (2017-09-30), pages 92106 - 92118 *
TAKEHARU IMAI等: "KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells", ANTICANCER RESEARCH, vol. 37, no. 1, 31 January 2017 (2017-01-31), pages 47 - 56 *
TAKEHARU IMAI等: "Overexpression of KIF11 in Gastric Cancer with Intestinal Mucin Phenotype", PATHOBIOLOGY, vol. 84, 27 July 2016 (2016-07-27) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654705A (zh) * 2018-09-11 2021-04-13 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用在治疗代谢疾病中的微小rna抑制剂
CN112654705B (zh) * 2018-09-11 2024-07-02 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用在治疗代谢疾病中的微小rna抑制剂
CN113621708A (zh) * 2020-03-30 2021-11-09 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN113621708B (zh) * 2020-03-30 2022-02-15 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN113025714A (zh) * 2021-03-23 2021-06-25 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
CN113025714B (zh) * 2021-03-23 2022-05-24 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
CN118831092A (zh) * 2024-09-19 2024-10-25 天津市第五中心医院 miR-200b-3p在制备治疗子宫内膜癌的药物中的应用
CN119144728A (zh) * 2024-11-19 2024-12-17 四川大学华西医院 原发性肝癌的MicroRNA标志物的引物、试剂盒和应用

Also Published As

Publication number Publication date
WO2019102268A1 (en) 2019-05-31
EP3714038A1 (en) 2020-09-30
CA3084575A1 (en) 2019-05-31
US20260109981A1 (en) 2026-04-23
JP2021507683A (ja) 2021-02-25
KR20250051794A (ko) 2025-04-17
AU2018372631B2 (en) 2025-06-05
KR20200088445A (ko) 2020-07-22
CN119033819A (zh) 2024-11-29
JP7463275B2 (ja) 2024-04-08
JP2024091644A (ja) 2024-07-05
BR112020010079A2 (pt) 2020-11-03
AU2018372631A1 (en) 2020-05-21
SG11202004680UA (en) 2020-06-29
US12473547B2 (en) 2025-11-18
US20210163932A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US20260109981A1 (en) Cellular compositions and methods of treatment i
US9279123B2 (en) Method for promoting angiogenesis, vascularization or vessel repair or for inhibiting tumor angiogenesis
US20150216892A1 (en) Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
JP5681955B2 (ja) 短いｒｎａ分子
US12281310B2 (en) Use of trinucleotide repeat RNAs to treat cancer
CN103476947A (zh) 寡聚体的增强的生物分布
EP1874931A1 (en) Micro rna
US20090286242A1 (en) MicroRNA Expression Profiling and Uses Thereof
CN108367020B (zh) 通过miR-200家族抑制来抑制肿瘤的方法
US8796238B2 (en) Short RNA mimetics
CN112236514A (zh) 改善细胞过继转移的持久性的组合物和方法
US9273313B2 (en) Activation of quiescent stem cells
WO2025155251A1 (en) Methods of treating dystrophinopathies
AU2016314698A1 (en) Micrornas for the treatment of heart diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201127

RJ01 Rejection of invention patent application after publication